Pharmaceutical Industry News Archive
Get news by email or subscribe to our news feeds.
News Archive for January 2013
January 2, 2013
- FDA Approves TB Drug Despite Some Concerns
- FDA: Drug to Prevent Blood Clots Approved
- Salix Drug for HIV Patients Wins FDA Approval
- Abbott Completes Separation of Research-Based Pharmaceuticals Business
- Vernalis plc and H.Lundbeck A/S Achieve Third Research Milestone
- Former Senior Teva Exec: Scrap IP
- Covidien Expects Better 2013 Pharmaceutical Sales
- FDA Clears Anticlotting Drug Eliquis
- CSL Behring Launches Its First Co-Pay Assistance Program to Ease Financial Burden of Treating Hereditary Angioedema
- AbbVie Celebrates Launch as New Biopharmaceutical Company with Employees, Patients
- Mylan Launches First Generic Maxalt MLT Tablets
- Microbiotix Announces Exclusive Worldwide Licensing Agreement for HCV NS5B Non-Nucleoside Polymerase Inhibitors
- FDA Clears OncoMed's Demcizumab (Anti-DLL4) to Resume Clinical Testing in the US
January 3, 2013
- NGM Enters Agreement With Janssen to Discover and Develop Novel Therapeutics for Diabetes
- Repligen Announces Licensing Agreement with Pfizer for Spinal Muscular Atrophy Program
- Forest Laboratories, Inc. Announces Additional Settlement Agreement in Bystolic Patent Litigation
- Cellular Dynamics Announces Agreement with AstraZeneca on Use of iPSC-derived Human Cells in Drug Discovery Research
- Sutro Biopharma to Collaborate with Sanofi Pasteur on a Novel Production Approach for Vaccine Candidates
- ProAir HFA (albuterol sulfate) with Dose Counter Now Available to Patients
- Bioniche Life Sciences Inc. Provides an Update on the Return of Urocidin Global Rights
January 4, 2013
- Tranzyme Pharma Announces Successful Completion of Drug Discovery Collaboration With Bristol-Myers Squibb
- Lilly Comments on 2012 Financial Guidance and Announces 2013 Financial Guidance
- Publicis Healthcare Communications Group Launches Publicis Health Media
January 7, 2013
- Evotec Expands Collaboration With MedImmune, Receives Milestone Payment
- Lilly reassumes sole worldwide development and commercialization rights for novel basal insulin analog
- MacroGenics and Gilead Sciences Enter Strategic Alliance to Develop and Commercialize Four DART Products
- Merck Announces FDA Acceptance of Resubmission of New Drug Application for Sugammadex Sodium Injection
- Sisters' Cancer-Drug Link Trial Begins
- Analyst Upgrades J&J, Sees All Segments Improving
- Endo Health Falls As It Lowers 2013 Forecasts
- ethris Announces Research Based Alliance on SNIM Modified RNA with Shire
- Athenahealth to Buy Epocrates for About $292M
- Intellipharmaceutics Announces Proposed Convertible Debenture Financing
- Peregrine Pharmaceuticals Provides Update on the Internal Review of Its Phase II Second-Line Non-Small Cell Lung Cancer Trial
- California Biomedical Companies Report Higher Product Approvals; Fewer Delays
- Medicines Company Completes Acquisition of Incline Therapeutics, Inc.
- Talon Therapeutics Announces Review of Strategic Alternatives
- Epizyme, Eisai and Roche to Develop EZH2 Companion Diagnostic
- Takeda and Affymax Announce Supply Agreement for Omontys (Peginesatide) Injection with DSI Renal
- Big pharma will increasingly tap M&A to close $100 billion growth gap, but path to deals grows more complex
January 8, 2013
- FDA approves Kineret for the treatment of NOMID
- Chugai and Debiopharm Group Announce an Exclusive License Agreement for Anti-Cancer Agent, FF284 (Debio 1347)
- BIND Biosciences and Amgen Sign Agreement For The Worldwide Development and Commercialization of a Kinase Inhibitor Nanomedicine
- Death Rates for Most Major Cancers Decline Slightly
- Vivus Rises on Latest Qsymia Prescription Report
- Many Doctors Prescribe Costlier Drugs Than Needed, Study Finds
- Adimab Expands Collaborations with Merck and Lilly
- Proteonomix Announces Restructuring
- Shire Acquires Lotus Tissue Repair, Inc.
- Abbott Initiates Clinical Trial of Absorb in the United States
January 9, 2013
- Cell Therapeutics Begins Enrollment in Phase 3 PERSIST-1 Trial of Pacritinib for the Treatment of Myelofibrosis
- Galapagos delivers candidate drug in GSK alliance and receives milestone payment
- Drug Developers Need to More Fully Identify and Address Root Causes of R&D Inefficiency, According to Tufts Center for the Study
- Daiichi Sankyo and Amplimmune Announce Strategic Alliance to Develop AMP-110 Therapy for Autoimmune Disease
- Sanofi Provides an Update on its Research & Development Pipeline
- Shire to Acquire Lotus Tissue Repair
- FDA issues draft guidance on abuse-deterrent opioids
January 10, 2013
- FDA Issues Draft Guidance on Abuse-deterrent Opioids
- FDA Issues Draft Guidance on Abuse-deterrent Opioids
- Analysts: Flu May Deliver Limited Impact to Stocks
- Teva Raises Copaxone Price Another 10 Percent
- Glaxo, Theravance Seek EU Approval of Lung Drug
- Gilead Sciences, Inc. Praised for Commitment on Chimpanzee Research
- Shionogi Files a Patent Infringement Action to Protect Intellectual Property Covering Crystal Form of Doribax in the US
- FDA OKs 3-Year Birth Control System
- Zolpidem Containing Products: Drug Safety Communication - FDA Requires Lower Recommended Doses Including Ambien, Ambien CR, Edluar, and Zolpimist
January 11, 2013
- Merck Provides Update on Next Steps for Tredaptive (extended-release niacin/laropiprant)
- Transcept Pharmaceuticals Comments on New FDA Dosage Reduction Requirements for Zolpidem Based Prescription Sleep Aids Administered at Bedtime
- Merck Warns Doctors to Stop Prescribing Tredaptive
- FDA Urges Lower Bedtime Doses of Insomnia Drug
- Eli Lilly Settles DES Cancer Lawsuit
January 14, 2013
- Abbvie Recalling Thyroid Drug
- Dendreon Shares Jump Following Upgrade
- Perrigo Falls Following Goldman Sachs Downgrade
- Animal Rights Activists Plan Direct Action Against Beagle Imports
- Pfizer Announces Availability Of Quillivant XR (methylphenidate hydrochloride) CII For Extended-Release Oral Suspension In The United States
January 15, 2013
- Avastin Misses Key Data Point in Brain Cancer Study
- Forest Laboratories, Inc. Reports Fiscal Year 2013 Third Quarter Earnings
- AstraZeneca announces changes to Senior Executive Team
- Change to the Roche Corporate Executive Committee
- Sanford-Burnham Medical Research Institute Announces John C. Reed, M.D., Ph.D., Resigns as Chief Executive Officer to Accept Position as Global Head of Pharma Research and Early Development for Roche
- Halozyme Climbs As Analyst Upgrades Stock
- Lance Armstrong Says He Doped Before Cancer Diagnosis: Source
January 16, 2013
- Galapagos delivers candidate drug in its alliance with Janssen Pharmaceutica NV and receives ?4 million milestone payment
- Conference Center, Hotel Eyed for Roche Site
- Analyst: Pfizer Spinoff No Need for Worry in Groton, Conn.
- Daiichi Sankyo and Ranbaxy to leverage synergies in Thailand
- Teva Looks to Asia
- Amgen To Build State-Of-The-Art Manufacturing Facility In Singapore
January 17, 2013
- Teijin Pharma to Launch Ipsen?s Somatuline Subcutaneous Injection in the Treatment of Acromegaly and Pituitary Gigantism in Japan
- Robust Biopharmaceutical Pipeline Offers New Hope for Patients
- Armstrong Confession Validates His Use of Performance-Enhancing Drugs
January 18, 2013
- FTC Study: In FY 2012, Branded Drug Firms Significantly Increased the Use of Potential Pay-for-Delay Settlements to Keep Generic Competitors off the Market
- Member of multi-State pharmaceutical theft scheme admits possession and sale of stolen goods
January 23, 2013
- HIV/AIDS Update - Kaletra (lopinavir/ritonavir) label update: drug interaction information
- Psivida Corp. Announces Final Published Guidance from U.K.'s Nice and Pursuit of Patient Access Scheme for Iluvien for DME
- Novartis delivers strong innovation in 2012, offsetting patent expirations; next growth phase expected to begin in 2013
- Dr. Jörg Reinhardt to leave Bayer HealthCare
- Watson Acquires Uteron Pharma SA
- Allergan, Inc. to Acquire MAP Pharmaceuticals, Inc.
- Merck Serono Announces the Creation of Ondaco, the Fifth Company Stemming From its Entrepreneur Partnership Program
- Ampio Pharma Says Eye Drug Trial Can Go Ahead
- Simcere Pharma Sells Stake in Shanghai Celgen
- Arena Slumps on Continued Concerns for Belviq
- Celsion Rises After Expanding China Partnership
- Abbott Reports Fourth-Quarter and Full-Year 2012 Results
- Johnson & Johnson CEO: Drug Makers Want Higher Payments From Government and Private Insurers
- Cytos to Regain Rights to Smoking Cessation Vaccine
January 24, 2013
- Baxter Announces Agreement to Acquire Investigational Hemophilia Compound OBI-1 and Related Assets
- Baxter Reports Record Sales, Earnings and Cash Flow for Full-Year 2012
- Ipsen and Inspiration Biopharmaceuticals Enter into an Asset Purchase Agreement with Baxter International on OBI-1
- Amgen's Full Year 2012 Revenues Increased 11 Percent To $17.3 Billion And Adjusted Earnings Per Share (EPS) Increased 22 Percent To $6.51
- Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2012 Financial Results
- Earns-Amgen
- Gilead Initiates Phase 3 Clinical Program for Tenofovir Alafenamide, a Novel Low-Dose Prodrug for the Treatment of HIV
- Seattle Genetics and Millennium Initiate Global Phase III Clinical Trial of Adcetris (Brentuximab Vedotin) in Front-line CD30-Expressing Mature T-Cell Lymphoma (MTCL)
January 25, 2013
- Allerject Canada's first 'talking' epinephrine auto-injector
- Merck Serono Initiates TH-302 Phase III MAESTRO Study in Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma
- Samsca (tolvaptan): Drug Warning - Potential Risk of Liver Injury
- U.S. Won't Pursue Case of Drug Representative and 'Off-Label' Promotion
- Actavis Predicts 2013 Profit Growth Short of Street
- Discontinuation of Development for the Additional Indication of Carpal-Tunnel Syndrome, for Limaprost, an Oral Prostaglandin E1 Analogue
January 28, 2013
- Biogen Idec 2012 Revenue Increases 9% to $5.5 Billion
- FDA Approves 3 New Diabetes Drugs From Takeda
- Medivir: Phase II all-oral combination studies of Simeprevir, TMC647055 and IDX719 for the treatment of Hepatitis C to be initiated shortly
- Earnings Preview: Pfizer to Focus on New Drug Oks
- Idenix Pharmaceuticals Announces Collaboration With Janssen to Initiate Phase II All-Oral Combination Studies Including IDX719, Simeprevir (TMC435) and TMC647055 for the Treatment of Hepatitis C Virus (HCV)
- Biogen 4Q Profit Slips on Tax Hit, Rising Costs
- Medicago Inc. and Mitsubishi Chemical Holdings Corporation Enter into a Collaboration to Develop a Next Generation Technology for Plant Production
January 29, 2013
- Pfizer Reports Fourth-Quarter and Full-Year 2012 Results; Provides 2013 Financial Guidance
- Lilly Reports Fourth-Quarter and Full-Year 2012 Results, Revises 2013 EPS Guidance
- Immunogen Slides As Analyst Cuts Rating
- Triangle Drug Company Specializes in Side-Effects of Cancer Therapy
- Merck Serono and Feinstein Institute to Partner on Pre-clinical Program in Inflammatory Diseases
- Afraxis Grants Exclusive Global License to Genentech
- As Congressman Works to Repeal Amgen Medicare Drug Exemption, Lobbyists Face Scrutiny
January 30, 2013
- JLL Partners to Acquire BioClinica and CoreLab Partners
- AbbVie Issues Inaugural Full-Year Outlook for 2013
- Pfizer Says It's Examinining Whether to Separate Its Management
- Roche Posts Modest Profit Gain for 2012
- Roche delivers strong 2012 results
- FDA Gives New Drug Application Approval to Isis
- Vertex Swings to Loss on Weak Hep C Drug Sales
- inVentiv Health Launches "Done as One" Integrated Services Model to Better Meet Global Demand for Unified Healthcare Communications Expertise
- Monthly News Round Up - January 2013
January 31, 2013
- Pfizer Wins RAPAMUNE Patent Case in Delaware District Court
- Lilly Supports the Medical Community's Testimony on the Clinical Utility of Beta-Amyloid Imaging Agents, Such as Amyvid(TM) (Florbetapir F 18 Injection), During CMS Public Hearing
- Teva Announces Termination of Agreements with CureTech
- AstraZeneca - Fourth Quarter and Full Year Results 2012
- European Medicines Agency update on Diane 35 and generics used in the treatment of acne
